Clinical trialsCompany release

Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3

🇺🇸 Kyntra Bio, Inc. (KYNB) · Mon 16 Nov 2026

After a Phase 2 interim analysis showed insufficient efficacy, the company is dropping two prostate cancer candidates and refocusing on roxadustat in lower-risk myelodysplastic syndromes, subject to funding.

Kyntra Bio, Inc. has stopped development of FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer. The company announced the decision with its third-quarter 2026 results on 16 November 2026, saying the Phase 2 interim analysis showed insufficient efficacy.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Kyntra Bio, Inc. ↗

Article written by VigiEye from the official source (Kyntra Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →